Compare IDAI & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDAI | ALUR |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | IDAI | ALUR |
|---|---|---|
| Price | $3.92 | $1.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $9.25 |
| AVG Volume (30 Days) | 93.7K | ★ 109.6K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,727,824.00 | ★ $17,208,000.00 |
| Revenue This Year | $3.46 | N/A |
| Revenue Next Year | $219.85 | $15.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 72.57 | N/A |
| 52 Week Low | $1.43 | $1.02 |
| 52 Week High | $5.28 | $7.40 |
| Indicator | IDAI | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 47.16 |
| Support Level | $3.80 | $1.28 |
| Resistance Level | $4.31 | $1.57 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 24.56 | 33.85 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.